Lilly’s Oral Obesity Pill

Eli Lilly’s new weight-loss pill, Foundayo, is reaching patients fast, but whether many can stay on it depends on what insurers will pay. (lilly.com) (npr.org) Foundayo, the brand name for orforglipron, won Food and Drug Administration approval on April 1, 2026, for adults with obesity or adults with overweight plus at least one weight-related condition. Lilly said prescriptions were accepted immediately, with shipping starting April 6 and broader pharmacy distribution to follow. (fda.gov) (lilly.com) The drug is a glucagon-like peptide-1, or GLP-1, pill, a class that mimics a gut hormone that helps people feel fuller and eat less. Lilly says Foundayo is taken once a day and, unlike some earlier oral GLP-1 medicines, does not come with food or water timing restrictions. (lilly.com) (foundayo.lilly.com) In Lilly’s ATTAIN-1 trial, adults taking the highest dose lost an average of 27 pounds, according to the company’s approval announcement. On April 16, Lilly also said a separate Phase 3 study met its main heart-safety goal in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. (lilly.com 1) (lilly.com 2) Early demand has been measurable. Analysts citing IQVIA data said Foundayo was prescribed 1,390 times in the U.S. in the week ended April 10, the drug’s first days on the market. (pharmexec.com) (reuters.com) Lilly is pitching price and convenience to widen access. The company said Foundayo starts at $25 a month for commercially insured patients and $149 a month for self-pay through LillyDirect, with free home delivery. (lilly.com 1) (lilly.com 2) Coverage remains the bigger gatekeeper. NPR reported this week that GoodRx found 12 million people lost coverage for Zepbound and another 12 million lost coverage for Wegovy from 2025 to 2026, showing how quickly obesity-drug benefits can change even after a drug reaches the market. (npr.org) That uncertainty now extends to Medicare. KFF said a proposed federal pilot called BALANCE could have expanded access to GLP-1 obesity drugs for some Medicare beneficiaries, but BioSpace reported on April 22 that the Centers for Medicare and Medicaid Services had indefinitely postponed the pilot after major insurers showed reluctance to participate. (kff.org) (biospace.com) Foundayo also arrived through an unusually fast review. The Food and Drug Administration said it approved the drug 50 days after filing under its Commissioner’s National Priority Voucher pilot, 294 days ahead of the original user-fee deadline, making it the first new molecular entity cleared under that program. (fda.gov) The next test is less about launch-week prescriptions than repeat fills. Lilly has put an oral GLP-1 on pharmacy shelves, but the size of the market will be set plan by plan, month by month, at the insurance counter. (pharmexec.com) (npr.org)